Preliminary updated results of a phase I/II trial using trimodality therapy in patients with post-prostatectomy high risk pathologic (p) T2-3N0M0 prostate cancer

被引:0
|
作者
Kumar, Parvesh
Van Veldhuizen, Peter J.
Thompson, Mark
Shen, Xinglei
Coster, James
Pinskl, Jacek
机构
[1] Univ Kansas, Sch Med, Dept Radiat Oncol, Kansas City, KS USA
[2] Univ Kansas, Sch Med, Div Med Oncol, Westwood, KS USA
[3] Univ So Calif, Keck Sch Med, Div Med Oncol, Los Angeles, CA 90033 USA
关键词
D O I
10.1200/jco.2014.32.15_suppl.e16084
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
e16084
引用
收藏
页数:1
相关论文
共 49 条
  • [41] Docetaxel (DOC), cisplatin (CIS) and gemcitabine (GEM) as neoadjuvant treatment in stage IIIAN2 and T4N0-1 non-small cell lung cancer (NSCLC) patients (P).: Final results of SLCG phase II trial 9901
    Garrido, P
    Rosell, R
    Torres, A
    Larriba, JG
    Provencio, M
    Isla, D
    Lago, J
    Astudillo, J
    Ronco, MS
    Tarón, M
    LUNG CANCER, 2005, 49 : S14 - S14
  • [42] Phase II Neoadjuvant Trial of Anthracycline Based Regimens Followed by a Combination with Nanoparticle Almumin-Bound Paclitaxel and Trastuzumab in Patients with Operable T2-3,N0-1,Her2 Positive Breast Cancer.
    Iwamoto, M.
    Takahashi, Y.
    Kimura, K.
    Tanaka, S.
    Uchiyama, K.
    CANCER RESEARCH, 2011, 71
  • [43] Adjuvant radiochemotherapy (RTx/CTx) using 5-FU/Folinic acid (FA)/cisplatin (DDP) ± Paclitaxel (P) and radiation in patients (pts) with completely (R0) resected high-risk gastric cancer (UICC stages II-IV(M0): An extended phase II study of the AIO/ARO/ACO
    Bokemeyer, Carsten
    Budach, Wilfried
    Stahl, Michael
    Vanhoefer, Udo
    Hehr, Thomas
    Wilke, Jochen
    Schleicher, Jan
    Schleucher, Nobert
    Kanz, Lothar
    Kollmannsberger, Christian
    ANNALS OF ONCOLOGY, 2004, 15 : 231 - 231
  • [44] Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels
    Shipley, W. U.
    Hunt, D.
    Lukka, H. R.
    Major, P.
    Heney, N. M.
    Grignon, D.
    Patel, M.
    Bahary, J.
    Lawton, C. A.
    Sandler, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [45] Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
    Lum, Lawrence G.
    Al-Kadhimi, Zaid
    Deol, Abhinav
    Kondadasula, Vidya
    Schalk, Dana
    Tomashewski, Elyse
    Steele, Patricia
    Fields, Kristie
    Giroux, Melissa
    Liu, Qin
    Flaherty, Lawrence
    Simon, Michael
    Thakur, Archana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (06)
  • [46] Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels
    Shipley, W. U.
    Hunt, D.
    Lukka, H.
    Major, P.
    Heney, N. M.
    Grignon, D.
    Patel, M.
    Bahary, J.
    Lawton, C.
    Sandler, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S27 - S27
  • [47] Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) plus abiraterone acetate plus prednisone (AA plus P) plus leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).
    McBride, Sean Matthew
    Spratt, Daniel Eidelberg
    Kollmeier, Marisa
    Abida, Wassim
    Xiao, Han
    Slovin, Susan F.
    Paller, Channing Judith
    Deville, Curtiland
    Den, Robert Benjamin
    Hearn, Jason W. D.
    Scher, Howard I.
    Zelefsky, Michael J.
    Rathkopf, Dana E.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] Overall survival (OS) in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) treated with enzalutamide (ENZA) plus androgen deprivation therapy (ADT) by high or low disease volume and progression to mHSPC (M0 at diagnosis) or de novo mHSPC (M1 at diagnosis): Post hoc analysis of the phase 3 ARCHES trial.
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun
    Szmulewitz, Russell Zelig
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Alcaraz, Antonio
    Alexeev, Boris
    Shore, Neal D.
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Yamada, Shunsuke
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [49] Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2-trial
    Harbeck, Nadia
    Gluz, Oleg
    Kuemmel, Sherko
    Christgen, Matthias
    Braun, Michael
    Aktas, Bahriye
    Luedtke-Heckenkamp, Kerstin
    Forstbauer, Helmut
    Grischke, Eva-Maria
    Schumacher, Claudia
    Darsow, Maren
    Krauss, Katja
    Nuding, Benno
    Thill, Marc
    Potenberg, Jochem
    Uleer, Christoph
    Warm, Mathias
    Fischer, Hans H.
    Malter, Wolfram
    Hauptmann, Michael
    Kates, Ronald
    Graeser, Monika
    Wuerstlein, Rachel
    Shak, Steve
    Baehner, Rick
    Kreipe, Hans
    Nitz, Ulrike
    CANCER RESEARCH, 2021, 81 (04)